Tue, 19 May 2026 21:56:17 +0800 Tue, 19 May 2026 21:56:17 +0800 https://www.d1med.com https://www.d1med.com https://www.d1med.com https://www.d1med.com https://www.d1med.com 60 https://www.d1med.com Tue, 19 May 2026 21:56:17 +0800
]]> 2023-11-06 10:28:12 https://www.d1med.com
]]> 2023-11-06 10:28:12 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com 2022-11-19 20:15:02 https://www.d1med.com
肠癌类器官-伊立替康药敏检测实例]]> 2022-11-19 20:14:38 https://www.d1med.com
肠癌类器官培养成功率高]]> 2022-11-19 20:14:13 https://www.d1med.com
以类器官为基础的肿瘤精准用药指导方案：2周左右出具肿瘤药物敏感报告，赢得癌症患者最佳的治疗时间。快速且精准，时效性国际领先。样本类]]> 2022-11-19 20:12:19 https://www.d1med.com
检测流程]]> 2022-11-19 20:03:21 https://www.d1med.com
独创精准的检测系统，稳定性高、重复性好、体内还原度高。]]> 2022-11-19 20:02:56 https://www.d1med.com
检测仅需2周，培养1周，药敏检测一周，快速且精准，时效性国际领先。]]> 2022-11-19 20:02:37 https://www.d1med.com
完成类器官技术自动化、标准化设备研发和生产]]> 2022-11-19 20:02:17 https://www.d1med.com
覆盖多种药物，靶向药、化疗药、细胞周期调控药物等]]> 2022-11-19 20:01:59 https://www.d1med.com
患者自身来源的肿瘤类器官代替患者完成药敏，为多药可选的患者提供精准用药指导]]> 2022-11-19 20:00:08 https://www.d1med.com
患者自身来源的肿瘤类器官的药敏结果能够为疑难 罕见肿瘤患者提供用药参考]]> 2022-11-19 19:59:45 https://www.d1med.com
多线耐药患者，其自身来源的肿瘤类器官能够预测药敏反应，为医生和患者提供用药参考和更优化的治疗方案]]> 2022-11-19 19:59:18 https://www.d1med.com
排除无效或效果不佳的药物，帮助医生和患者在短时间内筛选更精准的药物]]> 2022-11-19 19:58:57 https://www.d1med.com